natgillin/translations-raw huggingface dataset:
Measure 94 mL of purified water in a measuring cylinder.
Odmjerite 94 ml pročišćene vode u graduiranom cilindru.
Measure ALT, AST, alkaline phosphatase, total bilirubin, gamma-glutamyl transferase (gamma-GT) and serum albumin before initiation of treatment with Lojuxta.
Prije započinjanja liječenja Lojuxtom, potrebno je odrediti ALT, AST, alkalnu fosfatazu, ukupni bilirubin, gamaglutamiltransferazu (gama-GT) i serumske albumine.
Measure out the correct number of level scoops of granules into a container.
Izmjerite ispravan broj ravno napunjenih mjernih žličica s granulama u posudu.
Measure serum ALT, AST and bilirubin prior to initiation of Revolade, every 2 weeks during the dose adjustment phase and monthly following establishment of a stable dose.
Mjeriti serumski ALT, AST te bilirubin prije početka primjene lijeka Revolade, svaka 2 tjedna za vrijeme prilagodbe doze i mjesečno nakon uspostavljanja stabilne doze.
Measure the correct volume of water for the number of birds to be vaccinated (depends on devices used).
Izmjerite ispravan volumen vode za broj ptica koje će biti cijepljene (ovisno o uređaju koji se upotrebljava).
Measure the dose
Izmjerite dozu
Measure the liquid
Izmjerite tekućinu
Measure your blood sugar if possible and rest.
Ako možete, izmjerite razinu šećera u krvi i odmorite se.
measured by HI assay
mjereno HI analizom
measured by SRH assay ≥ 25 mm2
izmjereno SRH analizom ≥25 mm2
measured, no effect is expected.
Klinički ishod ovog opaženog
measured, no effect is expected.
nisu određivane, učinak nije očekivan.
measured, no interaction expected.
određivane, ne očekuju se interakcije.
Measurement loss considered
Uzimajući u obzir gubitak pri
Measurement loss considered
Uzimajući u obzir gubitak pri odmjeravanju
Measurement loss not considered
Ne uzimajući u obzir gubitak pri
Measurement loss not considered
Ne uzimajući u obzir gubitak pri odmjeravanju
Measurement of erythropoietin following multiple dose intravenous administration revealed a half-life of approximately 4 hours in healthy volunteers and a somewhat more prolonged half-life of approximately 5 hours in renal failure patients.
Mjerenje eritropoetina nakon višestrukih intravenski primijenjenih doza pokazala su da je poluvijek eritropoetina približno 4 sata kod zdravih dobrovoljaca i nešto duži, približno 5 sati, kod bolesnika s kroničnim zatajenjem bubrega.
Measurement of patients’ BRAF V600 mutation status was required.
U bolesnika je bilo potrebno odrediti status mutacije BRAF V600.
Measurement of plasma concentrations of testosterone has demonstrated the persistent pharmacological effect of the continuing presence of deslorelin in the circulation for at least six months following administration of the veterinary medicinal product.
Mjerenjem koncentracije testosterona u plazmi predočen je farmakološki učinak kontinuiranog prisustva deslorelina u cirkulaciji za najmanje 6 mjeseci od aplikacije veterinarsko medicinskog proizvoda. .
Measurements of ADP-induced ex vivo platelet aggregation at physiologic calcium concentrations (D- phenylalanyl-L-prolyl-L-arginine chloromethyl ketone anticoagulant) in patients presenting with unstable angina and Non Q-Wave Myocardial Infarction showed a concentration-dependent inhibition with an IC50 (50 % inhibitory concentration) of approximately 550 ng/ml and an IC80 (80 % inhibitory concentration) of approximately 1,100 ng/ml.
Mjerenja ADP-om inducirane ex vivo agregacije trombocita pri fiziološkim koncentracijama kalcija (D-fenilalanil-L- prolil-L-arginin klorometil keton antikoagulans) u bolesnika s nestabilnom anginom i non Q infarktom miokarda pokazala su inhibiciju ovisnu o koncentraciji s IC50 (50 % inhibitorne koncentracije) od približno 550 ng/ml i IC80 (80 % inhibitorne koncentracije) od približno 1100 ng/ml.
Measurements of ADP-induced ex vivo platelet aggregation at physiologic calcium concentrations (D- phenylalanyl-L-prolyl-L-arginine chloromethyl ketone anticoagulant) in patients presenting with unstable angina and Non Q-Wave Myocardial Infarction showed a concentration-dependent inhibition with an IC50 (50 % inhibitory concentration) of approximately 550 ng/ml and an IC80 (80 % inhibitory concentration) of approximately 1,100 ng/ml.
Mjerenja ADP-om inducirane ex vivo agregacije trombocita pri fiziološkim koncentracijama kalcija (D-fenilalanil-L- prolil-L-arginin klorometil keton antikoagulans) u bolesnika s nestabilnom anginom i non-Q infarktom miokarda pokazala su inhibiciju ovisnu o koncentraciji s IC50 (50 % inhibitorne koncentracije) od približno 550 ng/ml i IC80 (80 % inhibitorne koncentracije) od približno 1100 ng/ml.
Measurements of ADP-induced ex vivo platelet aggregation at physiologic calcium concentrations (Dphenylalanyl-L-prolyl-L-arginine chloromethyl ketone anticoagulant) in patients presenting with unstable angina and Non Q-Wave Myocardial Infarction showed a concentration-dependent inhibition with an IC50 (50 % inhibitory concentration) of approximately 550 ng/ml and an IC80 (80 % inhibitory concentration) of approximately 1,100 ng/ml.
Mjerenja ADP-om inducirane ex vivo agregacije trombocita pri fiziološkim koncentracijama kalcija (D-fenilalanil-L- prolil-L-arginin klorometil keton antikoagulans) u bolesnika s nestabilnom anginom i infarktom miokarda bez Q-zupca pokazala su inhibiciju ovisnu o koncentraciji s IC50 (50 % inhibitorne koncentracije) od približno 550 ng/ml i IC80 (80 % inhibitorne koncentracije) od približno 1100 ng/ml.
Measures of renal function (CLcr) and liver function (blood chemistry) indicate minimal effect of kidney and liver function on the pharmacokinetics of thalidomide.
Mjere funkcije bubrega (CLcr) i funkcije jetre (biokemijske pretrage krvi) upućuju na minimalne učinke funkcije bubrega i jetre na farmakokinetiku talidomida.
Measures to ensure that all appropriate actions have been performed prior to Odomzo being prescribed and dispensed
Mjere koje osiguravaju da su poduzete sve primjerene radnje prije propisivanja i izdavanja Odomza
Measuring of the calcium levels in the blood and/or urine
Mjerenje razine kalcija u krvi i/ili mokraći
Measuring spoon
Mjerna žličica
Measuring the dose of Omnitrope to be injected
Odmjeravanje doze Omnitropea za injekciju
Measuring the dose of PegIntron from the reconstituted powder for injection
Odmjeravanje doze lijeka PegIntron iz pripremljenog praška za injekciju
Measuring the dose of ViraferonPeg from the reconstituted powder for injection
Odmjeravanje doze lijeka ViraferonPeg iz pripremljenog praška za injekciju
Meat and offal:
Meso i jestive iznutrice:
Meat and offal: 1 47 days
Meso I iznutrice:47 dana
Meat and offal: 10 days
Meso i iznutrice 10 dana
Meat and offal: 13 days.
Svinja (meso i jestive iznutrice): 13 dana.
Meat and offal: 15 days (cattle)
Meso i iznutrice: 15 dana (goveda)
Meat and offal: 15 days (Cattle),
Meso i jestive iznutrice: 15 dana (Goveda), Meso i jestive
Meat and offal: 15 days (cattle), 5 days (pigs)
Meso i jestive iznutrice: 15 dana (goveda), 5 dana (svinje)
Meat and offal: 15 days (Cattle), Meat and offal: 5 days (Pigs
Meso i jestive iznutrice: 15 dana (Goveda), Meso i jestive iznutrice offal: 5 dana (Svinje)
Meat and offal: 15 days (Cattle), Meat and offal: 5 days (Pigs)
Meso i jestive iznutrice: 15 dana (Goveda), Meso i jestive
Meat and offal: 15 days (Cattle), Meat and offal: 5 days (Pigs)
Meso i jestive iznutrice: 15 dana (Goveda), Meso i jestive iznutrice: 5 dana (Svinje)
Meat and offal: 15 days (Cattle), Milk: 5 days (Cattle),
Goveda: Meso i jestive iznutrice:15 dana; mlijeko: 5 dana
Meat and offal: 15 days Milk: 5 days
Goveda: Meso i jestive iznutrice: 15 dana; mlijeko: 5 dana
Meat and offal: 15 days Milk: 5 days
Meso i jestive iznutrice: 15 dana Mlijeko: 5 dana
Meat and offal: 15 days; Milk: 5 days
Goveda: Meso i jestive iznutrice: 15 dana; mlijeko: 5 dana
Meat and offal: 23 days Milk:
Meso i jestive iznutrice: 23 dana Mlijeko:
Meat and offal: 3 days
Meso i iznutrice 3 dana.
Meat and offal: 3 days
Meso i jestive iznutrice: 3 dana
Meat and offal: 3 days
Meso i jestive iznutrice: 3 dana.
Meat and offal: 3 days.
Meso i jestive iznutrice: 3 dana
Meat and offal: 4 days Chicken:
Meso i jestive iznutrice: 4 dana Kokoši:
Meat and offal: 4 days.
Meso i jestive iznutrice : 4 dana.
Meat and offal: 5 days
Meso i iznutrice: 5 dana
Meat and offal: 5 days
Meso i jestive
Meat and offal: 5 days (Pigs)
iznutrice: 5 dana (Svinje)
Meat and offal: 5 days.
Meso i iznutrice: 5 dana
Meat and offal: 5 days.
Meso i jestive iznutrice: 5 dana
Meat and offal: 6 days
Meso i jestive iznutrice: 6 dana.
Meat and offal: 6 days, Eggs: Zero days
Meso i jestive iznutrice: 6 dana Jaja: nula dana
Meat and offal: 9 days
Meso I iznutrice:9 dana
Meat and offal: cattle: 22 days.
Meso i jestive iznutrice: goveda: 22 dana
Meat and offal: cattle: 22 days;
Meso i jestive iznutrice: goveda: 22 dana;
Meat and offal: Cattle: 64 days.
Meso i jestive iznutrice: Goveda: 64 dana.
Meat and offal: Cattle: 64 days;
Meso i iznutrice: Goveda:64 dana, Svinje:16 dana
Meat and offal: pigs: 13 days.
Meso i jestive iznutrice: svinje: 13 dana
Meat and offal: zero days
Meso i jestive iznutrice: nula dana
Meat and offal: Zero days.
Meso i iznutrice: nula dana.
Meat and offal: Zero days.
Meso i jestive iznutrice: nula dana.
Meat and offal:1 47 days
Meso I iznutrice:47 dana
Meat, milk and offal: Zero days.
Meso, mlijeko i iznutrice: 0 dana
Meat, milk and offal: Zero days.
Meso, mlijeko i iznutrice: 0 dana.
Meats, oily fish
meso, masna riba
Mecasermin is a human insulin-like growth factor-1 (rhIGF-1) produced by recombinant DNA technology.
Mekasermin je ljudski inzulinu sličan faktor rasta-1 (rhIGF-1) dobiven rekombinantnom DNK tehnologijom.
Mechanism and Risk Factors
Mehanizam i faktori rizika
Mechanism of action
ATK oznaka: V03AE08 Mehanizam djelovanja
Mechanism of action
Mehanizam djelovanja:
Mechanism of action and pharmacodynamic effect
Mehanizam djelovanja i farmakodinamički učinci
Mechanism of action Insulin
Mehanizam djelovanja Inzulin
Mechanism of action: entecavir, a guanosine nucleoside analogue with activity against HBV polymerase, is efficiently phosphorylated to the active triphosphate (TP) form, which has an intracellular half-life of 15 hours.
Mehanizam djelovanja: entekavir, nukleozidni analog gvanozina koji je aktivan protiv HBV polimeraze, učinkovito se fosforilira do aktivnog trifosfatnog (TP) oblika s unutarstaničnim poluvijekom od 15 sati.
Mechanism of action: Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1 ) antagonist.
Mehanizam djelovanja: irbesartan je snažan, oralno djelotvoran, selektivni antagonist receptora angiotenzina II (tip AT1).
Mechanism of action: Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1) antagonist.
Mehanizam djelovanja: irbesartan je snažan, oralno aktivan, selektivni antagonist receptora angiotenzina II (tip AT1).
Mechanism of action: The mechanism of action of ranolazine is largely unknown.
Mehanizam djelovanja: Mehanizam djelovanja ranolazina uvelike je nepoznat.
Mechanism of interaction
Mehanizam interakcija
Mechanism of interaction
Sažetak opisa svojstava lijeka za
Mechanism of interaction
Većina inhibitora tirozin
Mechanism unknown
Bolesnice koje
Mechanism unknown
inhibitorima (što uključuje
mechanism unknown
mehanizam nije poznat
Mechanism unknown.
koncentracija amprenavira nije
Mechanism unknown.
Nepoznati mehanizam.
Mechanism unknown.
U takvom
Mechanism unknown.
virološkog djelovanja.
Mechanism(s) of resistance
Mehanizam (mehanizmi) rezistencije
Mechanism:
(1,07-1,20)
Mechanism:
hranom
Mechanism:
inhibira
Mechanism:
istodobne primjene lijeka
Mechanism:
Mehanizam: BCRP
Mechanism:
Mehanizam: CYP3A4
Mechanism:
Mehanizam: inhibicija
Mechanism: BCRP
Mehanizam: BCRP
Mechanism: CYP2C19
Mehanizam:
Mechanism: CYP2C19 induction by ritonavir
Mehanizam: indukcija CYP2C19
Mechanism: CYP3A4
Esomeprazo l
Mechanism: CYP3A4
kliničke učinke.
Mechanism: CYP3A4
Mehanizam: CYP3A4
Mechanism: CYP3A4
Mehanizam: OATP1B
Mechanism: CYP3A4
uzrokuje
Mechanism: CYP3A4/P-
Mehanizam:
Mechanism: Effect on ciclosporin is due to CYP3A4
Mehanizam: Učinak na ciklosporin posljedica je inhibicije CYP3A4
Mechanism: Effect on tacrolimus is due to CYP3A4
Mehanizam: Učinak na ciklosporin posljedica je inhibicije CYP3A4
Mechanism: Effect on tacrolimus is due to CYP3A4
Mehanizam: Učinak na takrolimus
Mechanism: increase in dasabuvir possibly due
Mehanizam: povećanje
Mechanism: increase in dasabuvir possibly due
Mehanizam: povećanje izloženosti dasabuviru
Mechanism: OATP1B1
Mehanizam: OATP1B1
Mechanism: possibly due to UGT inhibition by paritaprevir, ombitasvir and dasabuvir.
Mehanizam: inhibicija CYP3A4
Mechanism: possibly due to UGT1A1
Mehanizam: mogao bi biti
Mechanism: possibly due to UGT1A1
Mehanizam: moguća posljedica inhibicije UGT1A1
Mechanism: UGT1A1
Mehanizam:
Mechanisms of bacterial resistance to ceftolozane/tazobactam include:
Mehanizmi bakterijske rezistencije na ceftolozan/tazobaktam uključuju:
Mechansim of action
Mehanizam djelovanja
Meda A/S Askerveien 61
10151 Tallinn
Meda A/S Askerveien 61
Meda Pharma SIA
Meda AB Pipers väg 2A S-170 09 Solna Sweden
Meda AB Pipers väg 2A S-170 09 Solna
Meda Health Sales Ireland Ltd.
Meda Health Sales Ireland Ltd., Unit 34/35, Block A
MEDA Pharma GmbH Guglgasse 15
MEDA Pharma B.V. Krijgsman 20
Meda Pharma SIA
España
Meda Pharma SIA Parda tn 4
MEDA Pharma B.V. Krijgsman 20
Meda Pharma SIA Ukmergės street 369A LT- 12142 Vilnius
Meda Pharma SIA Ukmergės street 369A LT-12142Vilnius
Meda Pharma SIA Ukmergės street 369A LT-12142 Vilnius
Meda Pharma SIA Ukmergės street 369A LT-12142Vilnius
MEDA Pharmaceuticals Switzerland GmbH представителство за България
MEDA Pharmaceuticals Switzerland GmbH, представителство за България
medac
EU/1/12/779/004
medac
kiselina medac
medac Zoledronic acid
kiselina medac Zoledronatna
MedDRA conventions for frequency are very common (1/10), common (1/100 to <1/10), uncommon (1/1,000 to <1/100), rare (1/10,000 to <1/1,000), very rare (<1/10,000), or not known (cannot be estimated from the available data) including isolated reports.
Učestalost nuspojava prema MedDRA-i su: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000) ili nepoznato (ne može se procijeniti iz dostupnih podataka) uključujući izolirana izvješća.
MedDRA Organ System
MedDRA organski sustav
MedDRA Organ system classes
MedDRA klasifikacija organskih sustava
MedDRA Organ system classes
MedDRA organski sustav
MedDRA Preferred Term
MedDRA preporučeni izraz
MedDRA preferred Term
MedDRA preporučeni pojam
MedDRA Preferred Term
Preporučeni izraz prema MedDRA-i
MedDRA Preferred Term (v.15.1)
MedDRA preporučeni pojam
MedDRA preferred term (Version 16).
Preporučeni pojam prema MedDRA klasifikaciji (verzija 16) .
MedDRA SOC
MedDRA organski sustav
MedDRA Standard System Organ Class
MedDRA standardna klasifikacija organskih sustava (SOC)
MedDRA Standard System Organ Class
MedDRA standradna klasifikacija organskih sustava
MedDRA Standard System Organ Class
MedDRA – klasifikacije organskih sustava
MedDRA Standard System Organ Class
Organski sustav prema MedDRA klasifikaciji
MedDRA Standard System Organ Class
Standardni organski sustav prema MedDRA-i
MedDRA system organ class
klasifikacija organskih sustava
MedDRA System Organ Class
Klasifikacija organskih sustava po MedDRA terminologiji
MedDRA System Organ Class
Klasifikaciji organskih sustava prema MedDRA
MedDRA system organ class
Me dDRA klasifikacija organskih sustava
MedDRA system organ class
MedDR A – klasifika cija organsk ih sustava
MedDRA system organ class
MedDR A – klasifika cija organski h sustava
MedDRA System Organ Class
MedDRA klasifikacija prema organskim sustavima
MedDRA system organ class
MedDRA klasifikacije organskih sustava
MedDRA System Organ Class
MedDRA razred organskog sustava
MedDRA System Organ Class
MedDRA – klasifikacija organskih sustava
MedDRA System Organ Class
MedDRA – klasifikacije organskih sustava
MedDRA system organ class
Organski sustav prema MedDRA klasifikaciji
MedDRA System Organ Class
Organski sustav prema MedDRA-i
MedDRA system organ class (SOC)
MedDRA – klasifikacije organskih sustava (eng.
MedDRA system organ classes
MedDRA-klasifikacija organskih sustava
MedDRA system organ classes
Organski sustav
MedDRA term
Pojam prema MedDRA- i
MedDRA ystem organ classes
MedDRA klasifikacija organskih sustava
MedDRA  Medical Dictionary for Regulatory Activities.
MedDRA  Medicinski rječnik za regulatorne poslove.
Median
46,4
Median
8,8 (5,7 - 12,8)
Median # previous NNRTIs
medijan broja prethodnih NNRTI
Median # previous NRTIs
medijan broja prethodnih NRTI
Median # previous PIs
medijan broja prethodnih IP
Median % change in MRI-T2 lesion volume
Medijan % promjena volumena T2 lezije na MRI-ju
Median % change in T2- hyperintense lesion volume
Medijan % promjene volumena hiperintenzivnih lezija T2
Median % reduction in daily OCS dose from baseline (95% CI)
Medijan % smanjenja dnevne doze OKS-a od početne vrijednosti (95% CI)
Median % Reductionc
Medijan % smanjenjac
Median (25th, 75th percentile)
Opioidna analgezija za oralni mukozitis: Medijan (25., 75. percentila) dana
Median (25th, 75th percentile) days of WHO Grade 2/3/4 oral mucositis
Medijan (25., 75. percentila) dana oralnog mukozitisa stupnja 2/3/4 prema ljestvici SZO
Median (25th, 75th percentile) days of WHO Grade 3/4 oral mucositis in affected patients
Medijan (25., 75. percentila) dana oralnog mukozitisa stupnja 3/4 prema ljestvici SZO u pogođenih bolesnika
Median (25th, 75th percentile) days of WHO Grade 3/4 oral mucositis**
Medijan (25., 75. percentila) dana oralnog mukozitisa stupnja 3/4 prema ljestvici SZO
Median (95 % C.I)
Medijan (95% CI)
Median (95 % C.I.)
Medijan (95% CI)
Median (95 % CI)
Medijan (95 % CI)
Median (95 % CI)
Medijan (95% CI)
Median (95% C.I.)
medijan (95% CI)
Median (95% CI) (months) 2.33 (2.17, 3.32) 4.21 (3.45, 4.86)
Medijan (95% CI) (mjeseci) 2,33 (2,17; 3,32) 4,21 (3,45; 4,86)
Median (95% CI) (months) 3.48 (2.14, 4.86) 2.83 (2.10, 3.52)
Medijan (95% CI) (mjeseci) 3,48 (2,14; 4,86) 2,83 (2,10; 3,52)
Median (95% CI)months 12.19 (9.66, 14.98) 9.36 (8.05, 10.68)
Medijan (95% CI) (mjeseci) 12,19 (9,66; 14,98) 9,36 (8,05; 10,68)
Median (Interquartile range)
Medijanc (interkvartilni raspon)
Median (m)
medijan (m)
Median (mean) % change in brain volume over 12 months
Medijan (srednja vrijednost) % promjene u volumenu mozga tijekom 12 mjeseci
Median (mean) % change in brain volume over 24 months
Medijan (srednja vrijednost) % promjene u volumenu mozga tijekom 24 mjeseca
Median (mean) number of Gd-enhancing lesions at Month 24
Medijan (srednja vrijednost) broja lezija pojačanih gadolinijevim (Gd) kontrastnim sredstvom nakon 24 mjeseca
Median (mean) number of Gd-enhancing lesions at Month 24
Medijan (srednja vrijednost) broja lezija pojačanih gadolinijevim (Gd) kontrastnim sredstvom u 24. mjesecu
Median (Min – Max)
medijan (min.-maks.)
Median (min, max): all patients
Medijan (min, maks): svi bolesnici
Median (minimum – maximum)
84,11 (11,073)
Median (minutes)
Medijan (minute)
Median (months) (95 % CI)
Medijan (mjeseci) (95 % CI)
Median (months) (95 % CI)
Medijan (mjeseci) 95 % CI
Median (months) (95% CI)d
Medijan (mjeseci) (95% CI)d
Median (months) (min – max)
Medijan (mjeseci) (min – maks)
Median (months) Hazard ratio
Medijan (mjeseci) Omjer hazarda
Median (months)1
Medijan (mjeseci)1
Median (Q1, Q3) change from baseline at Week 96 in total cholesterol to HDL-cholesterol ratio was
Medijan (Q1, Q3) promjene omjera ukupnog kolesterola i HDL kolesterola od početne vrijednosti u
Median (range) maximum serum concentrations of asparaginase activity were 2,324 U/l (1,625 – 4,819 U/l).
Medijan (raspon) maksimalnih koncentracija aktivnosti asparaginaze u serumu iznosio je 2324 U/l (1625 – 4819 U/l).
Median (range) serum trough asparaginase activities on days 18, 25, and 33 were 209 (42 – 330) U/l, 130 (6 – 424) U/l, and 32 (1 – 129) U/l, respectively.
Medijan (raspon) najnižih aktivnosti asparaginaze u serumu iznosio je 18. dana 209 (42 – 330) U/l, 25. dana 130 (6 – 424) U/l i 33. dana 32 (1 – 129) U/l.
Median (weeks)
Srednja vrijednost (tjedni)
Median (weeks) (95 % CI)
Srednja vrijednost (tjedni) (95% CI)
Median , wks (95% CI)
76,5 (68,5; 82,7)
Median 18.9 (95% CI: 16.0, 23.7) months
Medijan 18,9 (95% CI: 16,0; 23,7) mjeseca
Median 23.3 (95% CI:
Medijan 23,3 (95% CI:
Median 95% CI
Medijan 95% CI
Median [2.5 – 97.5% range]
Medijan [raspon: 2,5 – 97,5%]
Median [95% CI], months
Medijan [95%CI], mjeseci
Median [95% CI], months
Medijan[95%CI], mjeseci
Median [95% CI]. months
Medijan [95%CI], mjeseci
Median a
medijana
Median Absolute Neutrophil Count (cells x 109/l)
Medijan apsolutnog broja neutrofila (stanice
Median Absolute Neutrophil Count (cells x 109/l)
Medijan apsolutnog broja neutrofila (stanice x109/l)
Median age (range), years
Medijan dobi (raspon), godine
Median Age (years)
medijan dobi (godine)
Median age was 34 years and about 64 % were male patients, median CD4 cell count was 170 and 190 cells per mm3 in the Viramune twice daily and efavirenz groups, respectively.
Medijan dobi bio je 34 godine, a oko 64% bolesnika bili su muškarci, medijan broja CD4 stanica bio je 170 i 190 stanica po mm3 u skupini na Viramuneu dvaput dnevno i skupini na efavirenzu.
Median age was 34 years and about 64% were male patients, median CD4 cell count was 170 and 190 cells per mm3 in the Viramune twice daily and efavirenz groups, respectively.
Medijan dobi bio je 34 godine, a oko 64% bolesnika bili su muškarci, medijan broja CD4 stanica bio je 170 i 190 stanica po mm3 u skupini na Viramuneu dvaput dnevno i skupini na efavirenzu.
Median age was 47 years (range 20-74) in the siltuximab arm and 48 years (range 27-78) in the placebo arm.
Medijan dobi bio je 47 godina (raspon 20-74) u skupini liječenoj siltuksimabom i 48 godina (raspon 27-78) u skupini liječenoj placebom.
Median age was 51 years (range 18–70 years), with 21.9% of patients
Medijan dobi je iznosio 51 godinu (u rasponu od
Median age was 51 years (range 18–70 years), with 21.9% of patients ≥ 60 years of age.
Medijan dobi je iznosio 51 godinu (u rasponu od 18-70 godina), kod čega je 21,9% bolesnika bilo ≥60 godina.
Median age was 62 (32-86), 83 % of patients were men; 83.5 % were Caucasian; and 91 % were smokers.
Medijan dobi iznosio je 62 godine (32 – 86), 83% bolesnika bili su muškarci, 83,5% njih bili su bijelci, a 91% pušači.
Median age, years (min-max)
Medijan dobi, godine (min.-maks.)
Median and estimated rates of OS at 1 year and 2 years are presented in Table 3.
Medijan i predviđene stope OS nakon 1 godine i 2 godine prikazani su u tablici 3.
Median Annualised Bleeding Rates (ABR) in subjects evaluable for efficacy were 2.95 (interquartile range 1.01-4.35) for subjects on prophylaxis fixed weekly interval, 1.38 (interquartile range 0.00-3.43) for subjects on individualized interval and 17.69 (interquartile range 10.77-23.24) for subjects on demand.
Medijan godišnje stope krvarenja (GSK) u ispitanika u kojih se mogla procijeniti djelotvornost iznosio je 2,95 (interkvartilni raspon 1,01-4,35) u ispitanika koji su primali profilaksu u fiksnim tjednim intervalima; 1,38 (interkvartilni raspon 0,00-3,43) u ispitanika koji su primali profilaksu u individualiziranim intervalima i 17,69 (interkvartilni raspon 10,77-23,24) u ispitanika liječenih po potrebi.
Median annualised bleeding rates in subjects <12 years of age evaluable for efficacy were 1.97 (interquartile range 0.00-3.13).
Medijan godišnjih stopa krvarenja u ispitanika u dobi <12 godina u kojih se mogla procijeniti djelotvornost iznosio je 1,97 (interkvartilni raspon 0,00-3,13).
Median annualised bleeding rates in subjects evaluable for efficacy were 1.60 (interquartile range 0.0-4.69) for subjects in the individualised prophylaxis arm, 3.59 (1.86-8.36) for subjects in the weekly prophylaxis arm and 33.57 (21.14-48.69) for subjects in the on demand treatment arm.
Medijan godišnje stope krvarenja u ispitanika u kojih se mogla procijeniti djelotvornost iznosio je 1,60 (interkvartilni raspon: 0,0-4,69) za ispitanike u skupini koja je primala individualiziranu profilaksu, 3,59 (1,86-8,36) za ispitanike u skupini koja je primala tjednu profilaksu i 33,57 (21,14-48,69) za ispitanike u skupini koja se liječila prema potrebi.
Median attacks/two weeks
Medijan napadaja/dva tjedna
Median attacks/week
Medijan napadaja/tjedan